Popular on Rezul
- HandicapMD Brings Industry-Leading Online Handicap Parking Permit Services to Pennsylvania
- Aortem, Backed by Venturseed, Transforms Mobile and Gaming Development with an Open Source Platform and Expanding Developer Tools
- Vantiva Receives 2024 RDK "Distinguished Leader Award"
- Immigrant Artists Explore Cultural, Historical and Social Experiences in "Unlocked Identities" Exhibition
- Phinge's Plan to Save Free Speech and Give Everyone the Right to Personal Privacy and Ownership and Monetization of Their Online Data and Content
- GitKraken Launches DevEx Advance Partner Program to Help Atlassian Solution Partners Elevate Their Clients' Developer & DevOps Team Productivity
- Atlas Elite Entertainment Releases New Single "Forever"
- College Campus Safety: The Importance of Self Defense Keychains for Women
- Celebrating 30 Years: 2024 Diversity Visa Lottery Opens Oct. 2, Offering Life-Changing Opportunities for U.S. Immigration
- Empowering Educators with AI: Goosechase and DIGITAL Partner for the Future of Interactive Experiences
Similar on Rezul
- Situ Ve Offers a New Perspective on Love Amid the Rising Passport Bro Movement
- Scout & Cellar Becomes First Winery in Texas to Receive B Corp Certification
- CRH Healthcare Acquires Four Urgent Care Clinics in Georgia
- IGC Pharma Wins 2 Awards in Phase 1 of NIA's AI PREPARE Challenge, Advancing Alzheimer's Early Prediction Research
- Superior Thin Film Solar Panel Advancements Open Great Opportunities in the Rapidly Developing Aerospace and Related Sectors: Stock Symbol: ASTI
- New Study Reveals Alarming Cardiac Risks Associated with Electroshock Treatment
- Allegiant Management Group Launches New Website Following Recent Rebranding
- Quidax Launches $125,000 Crypto Innovation Pitch, Partners with Moonshot for TC Battlefield
- L-Strategies LLC terminates Angie Wong Miami Republican Committeewoman's contract with New Federal State of China NFSC
- Use Bitcoin to Earn Bitcoin - Innovative Layer 2 Solution for Bitcoin
Substantial Funding, Debt Resolution, HOPE Dividend, Successful Clinical Trial Towards Accelerated Drug Approval for Bipolar Depression: Nasdaq: NRXP
Rezul News/10676882
HOPE Therapeutic Subsidiary Focused on Developing a Best-in-Class Network of Clinics for Patients with Suicidal Depression and Related Disorders. HOPE is Planned to be Spun Out as a Separate Company to be Owned by NRXP Shareholders, and New Investors. Effort to be Funded Apart from NRXP.
WILMINGTON, Del. - Rezul -- For more information on $NRXP visit: https://www.nrxpharma.com/ OR https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
More on Rezul News
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
HIGHLIGHTS
Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.
Company Funded For New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101
Audit of HOPE Therapeutics Subsidiary Complete, SEC Filing of Spinout Planned for Current Quarter.
Secured $10.8 - $16.3 Million Convertible-Debt Funding from an Institutional Investor.
NRX-100 NDA for Suicidal Depression Based on Data from Four Clinical Trials in Nearly 1000 Participants Demonstrating Highly Significant Efficacy.
Ketamine Findings Confirmed in Published 43,000 Person Cohort Study.
More on Rezul News
Phase 2b/3 Trial Data Presented at the American Society of Clinical Psychopharmacology. Profile Demonstrates Possible Best in Class.
Plans to file New Drug Application for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101.
Stability Data Continues to Mature on Three Manufacturing Lots Required for the NRX-100 (IV ketamine) NDA filing.
Company Announced Alignment with FDA on its Pediatric Study Plan for NRX-100, Also a Requirement for Filing of NDA.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
More on Rezul News
- ProtectVirginia Petitions Virginia Dept of Environmental Quality for Cruise Ship Regulations
- Harbor Associates Acquires 211,000-SF Suburban San Diego Office Campus
- Campaign for Kindness: Floris UMC is bringing back respect, humility, and compassion this election season
- Eden Prairie Home Available for the First Time in 23 Years
- Situ Ve Offers a New Perspective on Love Amid the Rising Passport Bro Movement
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
HIGHLIGHTS
Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.
Company Funded For New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101
Audit of HOPE Therapeutics Subsidiary Complete, SEC Filing of Spinout Planned for Current Quarter.
Secured $10.8 - $16.3 Million Convertible-Debt Funding from an Institutional Investor.
NRX-100 NDA for Suicidal Depression Based on Data from Four Clinical Trials in Nearly 1000 Participants Demonstrating Highly Significant Efficacy.
Ketamine Findings Confirmed in Published 43,000 Person Cohort Study.
More on Rezul News
- Parade of Homes Winners Announced
- Kuester Management Group Outlines Tips for Choosing an HOA Management Company
- Real Estate Expert in Central Florida Advises Buyers on Timing the Market: Buy Now or Wait?
- CEO Seth Bame Leads Indio Management in Transformative Restoration of Marquita Court
- Scout & Cellar Becomes First Winery in Texas to Receive B Corp Certification
Phase 2b/3 Trial Data Presented at the American Society of Clinical Psychopharmacology. Profile Demonstrates Possible Best in Class.
Plans to file New Drug Application for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101.
Stability Data Continues to Mature on Three Manufacturing Lots Required for the NRX-100 (IV ketamine) NDA filing.
Company Announced Alignment with FDA on its Pediatric Study Plan for NRX-100, Also a Requirement for Filing of NDA.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
Filed Under: Business
0 Comments
Latest on Rezul News
- Stop Fighting, Start Living. Daryl Dittmer's New Book Offers Roadmap to Personal Power
- NC Local Realtor® Achieves National Recognition
- 3 bed, 2 bath home coming soon to the market in Ramsey, MN!
- For Sale in Cambridge, MN is this walkout rambler built in 2021!
- Hyland Trail announces opening of four new model homes
- BTR: Understanding the Critical 2FA Vulnerability in QR Code Enrollment Processes Uncovered by Silent Sector – Lauro Chavez
- United Capital Group : The Leading Partner for Hotel Acquisition, Management & Financing
- IGC Pharma Wins 2 Awards in Phase 1 of NIA's AI PREPARE Challenge, Advancing Alzheimer's Early Prediction Research
- St George Utah Homes for Sale | All Listings, Easy to Search
- Cressent Property Group LLC Partners With Jacksun Inc
- Get in the Halloween Spirit at Rare Books LA Union Station
- HostWorldServices Expands Services to the General Public, Launches Innovative Hosting Solutions
- Titan Pressure Washing Demonstrates How to Pressure Wash Driveways At Low PSI to Preserve Pavers
- Join Us for the Space Coast HBCA Parade of Homes!
- Danielle Andrews Elected as 2025 Director for the Tallahassee Board of REALTORS®️
- Superior Thin Film Solar Panel Advancements Open Great Opportunities in the Rapidly Developing Aerospace and Related Sectors: Stock Symbol: ASTI
- Broker App Stack Introduces BrokerMatch AI
- Launch of Gibraltar Capital Partners, LLC: A Full-Service Real Estate Development & Investment Firm
- Grand opening of the ResC4EU platform to support companies withstanding supply chain disruptions
- New Study Reveals Alarming Cardiac Risks Associated with Electroshock Treatment